The 2 nd step of the project has been completed: the effectiveness and bioavailability of the ingredients developed by Deinove have been...
Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...
23.07.2017 to 26.07.2017
Emmanuel PETIOT, CEO of DEINOVE will be one of the speakers. More Info
19.06.2017 to 22.06.2017
Dominique LE BELLER, CEO of the DEINOBIOTICS subsidiary, to participate to the congress alongwith the "Nutrition Santé Longévité" French...